Harrow, Inc. (NASDAQ:HROW) is Diametric Capital LP’s 2nd Largest Position

Diametric Capital LP boosted its stake in shares of Harrow, Inc. (NASDAQ:HROW) by 49.0% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 110,295 shares of the company’s stock after purchasing an additional 36,269 shares during the period. Harrow comprises approximately 2.5% of Diametric Capital LP’s holdings, making the stock its 2nd largest position. Diametric Capital LP owned approximately 0.31% of Harrow worth $3,700,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in Harrow in the third quarter worth approximately $29,000. AlphaQuest LLC lifted its stake in shares of Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company’s stock valued at $118,000 after purchasing an additional 2,889 shares during the last quarter. Virtu Financial LLC bought a new stake in Harrow in the third quarter worth $271,000. Maridea Wealth Management LLC acquired a new position in Harrow during the fourth quarter worth $222,000. Finally, KLP Kapitalforvaltning AS bought a new position in Harrow during the fourth quarter valued at about $235,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $26.60 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business has a 50 day moving average price of $28.76 and a 200 day moving average price of $37.86. The company has a market cap of $947.36 million, a price-to-earnings ratio of -28.30 and a beta of 0.69. Harrow, Inc. has a twelve month low of $9.86 and a twelve month high of $59.23.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Thursday, March 27th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The company had revenue of $66.83 million during the quarter, compared to analysts’ expectations of $66.01 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HROW. B. Riley decreased their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $57.00 price objective on shares of Harrow in a report on Monday.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.